Compare Chart Industries Inc (GTLS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chart Industries Inc vs Viatris Inc — how do they compare? Chart Industries Inc trades at $209.97 (market cap $10.05B), while Viatris Inc trades at $16.6 (market cap $19.44B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.88% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| GTLS | VTRS | |
|---|---|---|
Market Cap | $10.05B | $19.44B |
Sector | Technology | Health |
52-Week High | $209.91 | $17.39 |
52-Week Low | $167.29 | $8.74 |
Enterprise Value | $13.57B | $31.65B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GTLS trades at $209.97, up 0.03% on the day, with a bullish technical outlook supported by moving averages but overbought RSI signals. The company reported $4.26B in 2025 revenue but missed earnings estimates for three consecutive quarters, with a negative net income margin of -0.62%. Recent news highlights Baker Hughes' pending $13.6B acquisition, which received conditional EU approval in July 2026, potentially driving investor optimism.
The stock's outlook is mixed: strong analyst buy consensus (54%) and acquisition prospects offer upside, but weak profitability and earnings misses pose risks. Investors should weigh the acquisition's completion against fundamental challenges like negative ROE and high P/E of 629.67, indicating premium valuation despite profitability concerns.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
